FDA, industry look to revisit regulatory framework for HCT/Ps
Regulatory NewsJoanne S. Eglovitch
Advanced therapies/cell and gene therapyCBERHuman cells, tissues, and cellular and tissue-based products (HCT/Ps)Quality Assurance and ControlRegulatory Intelligence/PolicyRisk managementUnited StatesUS Food and Drug Administration (FDA)